April 18–19, 2018Boston Convention & Exhibition CenterBoston, MA

BIOMEDevice Boston 2018 Schedule Viewer

View, browse, and sort the education offerings, networking opportunities, and event activities by using the filters below; you can search by Pass Type, Free Content & Activities, and Conference Track. With this session scheduler, you can build your daily agenda in advance and access the full list of options during the event. Sessions do fill up and seating is first come/first serve, so please arrive early to sessions that you would like to attend.

Alexis Sauer-BudgeManaging ScientistExponent

Dr. Sauer- Budge specializes in the intersection between biology and materials. Trained in chemistry and biophysics, she applies her interdisciplinary experience to development and failure analysis of clinical diagnostics, medical wearables, and regenerative medicine. She has particular expertise in biosensors, sample preparation, microfluidics, anti-fouling coatings, continuous monitoring of biomarkers, implants, 3D bioprinting, bench-top instrumentation, and multi-functional surgical tools. Dr. Sauer-Budge assists clients in device and diagnostics design, assay development (immunoassays, nucleic acid tests, cell-based assays), biocompatible/non-fouling coatings, scale-up for manufacturing, and strategic market analysis. Dr. Sauer-Budge works with companies at all stages as well as in the government sector. She is an active participant in peer review, including serving as a standing member of an NIH review committee and has published more than 35 articles. An accomplished inventor, she often participates in the assessment and protection of intellectual property. Prior to joining Exponent, Dr. Sauer-Budge led the biomedical/biotechnology group at the Fraunhofer Center for Manufacturing Innovation at Boston University for 10 years. She worked in the space between academia and industry, conducting applied research in the areas of medical diagnostics, devices, and instrumentation. She managed translational programs, helping to transition technologies from the bench through scale-up and FDA readiness. Prior to Fraunhofer, Dr. Sauer-Budge worked at BioScale, a start-up focused on commercializing a bioMEMs resonating membrane platform technology for the clinical diagnostic and food safety markets. Her graduate work was in the laboratory of Prof. Daniel Branton developing single molecule sequencing technologies that is now commercialized by Oxford Nanopore.

Presenting: